Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer

被引:202
作者
Ding, Pei-Rong [1 ,2 ]
An, Xin [2 ,3 ]
Zhang, Rong-Xin [1 ,2 ]
Fang, Yu-Jing [1 ,2 ]
Li, Li-Ren [1 ,2 ]
Chen, Gong [1 ,2 ]
Wu, Xiao-Jun [1 ,2 ]
Lu, Zhen-Hai [1 ,2 ]
Lin, Jun-Zhong [1 ,2 ]
Kong, Ling-Heng [1 ,2 ]
Wan, De-Sen [1 ,2 ]
Pan, Zhi-Zhong [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Dept Colorectal Surg, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
[2] State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
关键词
Neutrophil to lymphocyte ratio; Colon cancer; Stage IIA; MICROSATELLITE-INSTABILITY STATUS; ADJUVANT CHEMOTHERAPY; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; NODE RETRIEVAL; SURVIVAL; IMPACT; EXPRESSION; NUMBER;
D O I
10.1007/s00384-010-1052-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Objectives Adjuvant chemotherapy for stage II colon cancer remains controversial but may be considered for patients with high-risk features Recent studies have shown that elevated neutrophil to lymphocyte ratio (NLR) is a worse prognostic factor and a predictor of response to chemotherapy in patients with advanced colorectal cancer The purpose of this study was to evaluate whether NLR predicts risk of recurrence in patients with stage IIA colon cancer undergoing curative resection without adjuvant chemotherapy Methods We retrospectively reviewed 141 consecutive patients with stage IIA colon cancer treated with curative surgery alone from 2002 to 2006 NLR, as well as demographics, clinical, histopathologic, and laboratory data were analyzed Univariate and multivariate analyses were conducted to identify prognostic factors associated with recurrent-free survival (RFS) Results Cox's regression analysis demonstrated that elevated NLR (>4) (hazard ratio, 4 88, P<0 01) and less lymph node sampling (<15 lymph nodes, hazard ratio, 3 80, P<0 05) were adverse prognostic factors for RFS The 5-year RFS was 91 4% (95% Cl, 88 6-94 2%) for patients with normal NLR and 63 8% (51 1-76 3%) for patients with elevated NLR The 5-year RFS for patients with 0, 1, and 2 of the identified risk factors was 95 1%, 87 4%, and 33 3%, respectively (P<0 001) Conclusions Elevated preoperative NLR is an independent predictor of worse RFS for patients with stage IIA colon cancer and a potential biomarker to identify candidates for adjuvant chemotherapy
引用
收藏
页码:1427 / 1433
页数:7
相关论文
共 32 条
  • [1] [Anonymous], 2002, AJCC CANC STAG MAN
  • [2] Stage II colon cancer prognosis prediction by tumor gene expression profiling
    Barrier, Alain
    Boelle, Pierre-Yves
    Roser, Francois
    Gregg, Jennifer
    Tse, Chantal
    Brault, Didier
    Lacaine, Francois
    Houry, Sidney
    Huguier, Michel
    Franc, Brigitte
    Flahault, Antoine
    Lemoine, Antoinette
    Dudoit, Sandrine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) : 4685 - 4691
  • [3] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB
    Schrag, D
    Somerfield, MR
    Cohen, AM
    Figueredo, AT
    Flynn, PJ
    Krzyzanowska, MK
    Maroun, J
    McAllister, P
    Van Cutsem, E
    Brouwers, M
    Charette, M
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3408 - 3419
  • [4] Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
    Cho, HanByoul
    Hur, Hye Won
    Kim, Sang Wun
    Kim, Sung Hoon
    Kim, Jae Hoon
    Kim, Young Tae
    Lee, Kook
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) : 15 - 23
  • [5] Pathologic determinants of survival after resection of T3NO (Stage IIA) colorectal cancer: Proposal for a new prognostic model
    Cianchi, Fabio
    Messerini, Luca
    Comin, Camilla Eva
    Boddi, Vieri
    Perna, Federico
    Perigli, Giuliano
    Cortesini, Camillo
    [J]. DISEASES OF THE COLON & RECTUM, 2007, 50 (09) : 1332 - 1341
  • [6] Tumor thymidylate synthase 1494de16 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment
    Dotor, E
    Cuatrecases, M
    Martínez-Iniesta, M
    Navarro, M
    Vilardell, F
    Guinó, E
    Pareja, L
    Figueras, A
    Molleví, DG
    Serrano, T
    de Oca, J
    Peinado, MA
    Moreno, V
    Germà, JR
    Capellá, G
    Villanueva, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) : 1603 - 1611
  • [7] Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients
    Gal, R
    Sadikov, E
    Sulkes, J
    Klein, B
    Koren, R
    [J]. DISEASES OF THE COLON & RECTUM, 2004, 47 (07) : 1216 - 1224
  • [8] Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much?
    Gill, S
    Loprinzi, CL
    Sargent, DJ
    Thomé, SD
    Alberts, SR
    Haller, DG
    Benedetti, J
    Francini, G
    Shepherd, LE
    Seitz, JF
    Labianca, R
    Chen, W
    Cha, SS
    Heldebrant, MP
    Goldberg, RM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1797 - 1806
  • [9] Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma
    Gomez, D.
    Farid, S.
    Malik, H. Z.
    Young, A. L.
    Toogood, G. J.
    Lodge, J. P. A.
    Prasad, K. R.
    [J]. WORLD JOURNAL OF SURGERY, 2008, 32 (08) : 1757 - 1762
  • [10] Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma
    Gomez, Dhanwant
    Morris-Stiff, Gareth
    Toogood, Giles J.
    Lodge, J. Peter A.
    Prasad, K. Rajendra
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2008, 97 (06) : 513 - 518